Sildenafil (Generic) vs Vardenafil (Levitra/Staxyn): Side-Effect Profile Head-to-Head

How PDE5 Inhibitors Cause Side Effects

Both sildenafil and vardenafil block phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic GMP in penile smooth muscle. By raising cyclic GMP levels, they enhance nitric oxide-mediated vasodilation and improve erections 1. The same vasodilatory mechanism, however, acts on blood vessels throughout the body. That is why headache, flushing, and nasal congestion appear in virtually every PDE5 inhibitor trial.

Why Selectivity Matters

PDE5 is not the only phosphodiesterase in the body. There are 11 PDE families. Sildenafil and vardenafil differ in how strongly they bind to non-PDE5 isoforms, and those off-target interactions explain their divergent side-effect signatures 3.

Sildenafil has roughly 10-fold less selectivity for PDE6 (found in retinal photoreceptors) compared to vardenafil. That is why sildenafil, not vardenafil, causes visual color changes. Vardenafil, on the other hand, shows a measurable effect on cardiac repolarization (QTc interval) that sildenafil does not demonstrate at therapeutic doses 6.

Shared Mechanism, Different Clinical Profiles

Two drugs in the same class can still behave differently in the body. Think of it this way: both aspirin and ibuprofen inhibit cyclooxygenase, but their risk profiles diverge. The same principle applies here. The pharmacokinetic and selectivity differences between sildenafil and vardenafil produce clinically distinct adverse-event patterns worth examining in detail.

Headache, Flushing, and Dyspepsia: The Common Trio

These three adverse events dominate every PDE5 inhibitor dataset. A 2009 systematic review in the Annals of Internal Medicine pooled 118 trials of oral PDE5 inhibitors and confirmed that headache and flushing were the most frequently reported events across all agents 4.

Headache Rates

In the landmark Goldstein et al. Trial (N=532), sildenafil produced headache in 16% of patients at 50 mg and up to 28% at the maximum recommended dose 1. Vardenafil headache rates in the Porst et al. Trial (N=452, diabetic population) ranged from 15% to 21% across the 10 mg and 20 mg dose groups 2. Direct cross-trial comparison is imperfect because patient populations differed (Porst studied men with diabetes, who may have different baseline vascular profiles). Still, the headache burden appears broadly similar.

Flushing

Sildenafil flushing rates range from 10% to 18% depending on dose. Vardenafil flushing rates run slightly lower, at 11% to 13% in phase III data 3. The difference is modest and may not be clinically significant for most patients.

Dyspepsia

Sildenafil has a higher dyspepsia signal. FDA labeling reports rates of 7% to 17% at therapeutic doses. Vardenafil dyspepsia rates are lower, generally 4% to 6% 4. If a patient reports significant heartburn or stomach discomfort on sildenafil, vardenafil may be the more tolerable option. Taking either medication after a heavy, high-fat meal can also worsen GI symptoms and delay absorption.

Visual Disturbances: Sildenafil's Signature Side Effect

This is the single most distinguishing adverse event between the two drugs.

The PDE6 Connection

Sildenafil inhibits PDE6 in retinal rod and cone photoreceptors at concentrations achievable with standard oral dosing. PDE6 breaks down cyclic GMP in the phototransduction cascade. When sildenafil blocks PDE6, it transiently alters light sensitivity and color discrimination 5.

The clinical result is cyanopsia, a blue-green tinge to vision that patients often describe as "everything looks slightly blue." In FDA-reviewed data, visual disturbances (including altered color perception, increased light sensitivity, and blurred vision) occurred in approximately 3% of patients at 50 mg and up to 11% at 100 mg 1.

Vardenafil's Visual Profile

Vardenafil is approximately 15-fold more selective for PDE5 over PDE6 compared to sildenafil 3. In clinical trials, visual adverse events with vardenafil were reported at rates indistinguishable from placebo (<2%). Patients who work in color-critical professions (pilots, graphic designers, electricians reading wire colors) may prefer vardenafil for this reason alone.

Clinical Significance

For most men, sildenafil-related cyanopsia is mild, transient, and resolves within 3 to 5 hours. It is not associated with structural retinal damage in healthy eyes. The American Academy of Ophthalmology notes that PDE5 inhibitor-associated visual symptoms are dose-dependent and self-limiting in patients without pre-existing retinal disease 5. Patients with retinitis pigmentosa (a condition involving genetic PDE6 dysfunction) should avoid all PDE5 inhibitors, but the risk is most clearly documented with sildenafil.

QTc Prolongation: Vardenafil's Cardiac Signal

This is vardenafil's most clinically consequential differentiator.

What the Data Shows

In a thorough QT study, vardenafil 10 mg produced a mean QTc increase of approximately 4 milliseconds. At supratherapeutic doses (80 mg, four times the standard dose), the mean increase reached 8 ms. Moxifloxacin (the positive control) produced a 10 ms increase 6. The FDA mandated a specific labeling warning: vardenafil should not be used in patients taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol).

Decision Framework: When QTc Matters

A prescriber evaluating which PDE5 inhibitor to choose should apply a three-question cardiac screen:

1. Is the patient on any QTc-prolonging medication? (Check the CredibleMeds list.)
2. Does the patient have congenital long QT syndrome or a family history of sudden cardiac death?
3. Is the patient's baseline QTc >450 ms on a recent ECG?

If the answer to any of these is yes, sildenafil is the safer PDE5 inhibitor choice. If the answer to all three is no, vardenafil's QTc effect is unlikely to be clinically meaningful at standard doses.

Sildenafil's Cardiac Profile

Sildenafil does not produce clinically significant QTc prolongation at doses up to 200 mg in thorough QT studies. Its cardiovascular concern is different: sildenafil produces a modest drop in systolic blood pressure (8 to 10 mmHg on average), which is clinically relevant only in patients on nitrates (absolute contraindication for both drugs) or alpha-blockers 1. Both sildenafil and vardenafil are contraindicated with organic nitrates. That rule is non-negotiable.

Nasal Congestion and Back Pain

Nasal Congestion

Vardenafil produces nasal congestion more frequently than sildenafil. Phase III data show rates of 9% to 10% for vardenafil versus 4% for sildenafil 4. For men who already have chronic rhinitis or use CPAP for obstructive sleep apnea, this difference could affect nighttime breathing comfort.

Back Pain and Myalgia

Back pain appears in vardenafil trial data at 2% to 4%, slightly above placebo. Sildenafil has a similar low-grade signal. Neither drug produces the pronounced myalgia/back pain seen with tadalafil (which inhibits PDE11 in skeletal muscle). This is one category where the two drugs are nearly interchangeable in tolerability.

Discontinuation Rates and Serious Adverse Events

The 2009 Tsertsvadze et al. Systematic review (67 head-to-head and placebo-controlled trials, N=20,325 across all PDE5 inhibitors) found discontinuation-due-to-adverse-events rates of 2.5% for sildenafil and 1.9% for vardenafil 4. Both figures are low and fall within the range expected for well-tolerated oral medications.

Serious Adverse Events

Serious cardiovascular events (myocardial infarction, stroke) have been reported with all PDE5 inhibitors at post-marketing surveillance rates that do not exceed background population risk. The Tsertsvadze review found no statistically significant difference in serious adverse event rates between any PDE5 inhibitor and placebo after excluding nitrate co-administration 4.

Drug-Drug Interaction Profile

Both drugs are metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) significantly increase plasma levels of both drugs and require dose reduction. Vardenafil also has a minor CYP2C9 metabolic pathway. Grapefruit juice can increase levels of both drugs, though the effect is more pronounced with sildenafil. The American Urological Association guidelines recommend starting at the lowest dose when CYP3A4 inhibitors are present 7.

Special Populations

Men with Diabetes

The Porst et al. Trial specifically studied vardenafil in men with diabetes and ED (N=452). Vardenafil 10 mg and 20 mg improved IIEF-EF domain scores by 5.3 and 6.4 points, respectively, with an adverse event profile consistent with the general ED population 2. Sildenafil has similar efficacy data in diabetic populations from the Goldstein trial subgroup analyses. The choice between the two in diabetic men should be driven by the cardiac and visual considerations described above, not by efficacy differences.

Older Adults

Men over 65 have reduced hepatic clearance of both drugs. The FDA recommends starting sildenafil at 25 mg in patients over 65. Vardenafil's starting dose recommendation is 5 mg in the same population. Headache and flushing rates in older adults track slightly lower than in younger cohorts, possibly because of reduced vasoreactivity 4.

Men on Antihypertensives

Both drugs interact with alpha-blockers (doxazosin, tamsulosin). The blood pressure drop with sildenafil and doxazosin co-administration can exceed 25 mmHg systolic. If an alpha-blocker is necessary, vardenafil labeling recommends a 6-hour dosing separation, while sildenafil labeling recommends starting at the 25 mg dose with caution 6.

Switching Between Sildenafil and Vardenafil

No washout period is required when switching from one PDE5 inhibitor to another. Both drugs have short half-lives (3 to 5 hours). A common clinical approach: wait 24 hours after the last dose of the first drug, then start the new agent at the lowest recommended dose.

The European Association of Urology guidelines state that failure or intolerance of one PDE5 inhibitor does not predict failure with another, and a trial of at least four to six doses on a second agent is reasonable before concluding class-wide intolerance 8.

When to Switch

Consider switching from sildenafil to vardenafil if the patient reports bothersome visual changes at effective sildenafil doses. Consider switching from vardenafil to sildenafil if the patient has a new QTc-prolonging medication, develops a cardiac conduction abnormality, or reports persistent nasal congestion interfering with sleep.

Side-Effect Summary Table

| Adverse Event | Sildenafil (50 to 100 mg) | Vardenafil (10 to 20 mg) | |---|---|---| | Headache | 16 to 28% | 15 to 21% | | Flushing | 10 to 18% | 11 to 13% | | Dyspepsia | 7 to 17% | 4 to 6% | | Nasal congestion | ~4% | 9 to 10% | | Visual changes (cyanopsia) | 3 to 11% | <2% (similar to placebo) | | Back pain | 2 to 3% | 2 to 4% | | Dizziness | 2 to 4% | 2 to 3% | | QTc prolongation signal | No | Yes (mean +4 ms at 10 mg) | | Discontinuation rate (AE) | ~2.5% | ~1.9% |